semaglutide and ovarian cancer metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial Semaglutide: What we know about

Dana Taylor: What kinds of medical risks are doctors most worried about here

Be cautious with these claims

Clinicians should address body image concerns sensitively and provide evidence-based information to counter misinformation circulating online

Emerging biomarker platforms, including microRNA profiling and high-throughput proteomic and lipidomic signatures, together with advanced imaging approaches such as MRI-visible nano-GLP-1RA formulations, provide novel tools to monitor molecular and spatial drug effects in vivo

Pioglitazone is unlikely to pass into breastmilk in clinically significant amounts due to its drug properties

10.1152/japplphysiol.00157.2014 64 OlesenJ